SCIENCE NEWS Cells ‘Feel’ the Difference Between Stiff or Soft and Thick or Thin Matrix Cultured mesenchymal stem cells can “feel” at least several microns below the surface of an artificial microfilm matrix, gauging the elasticity of the extracellular bedding that is a crucial variable in determining their fate. [Press release from EurekAlert! discussing research presented at American Society of Cell Biology 50th Annual Meeting]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) Lineage Restriction of Human Hepatic Stem Cells to Mature Fates Is Made Efficient by Tissue-Specific Biomatrix Scaffolds Biomatrix scaffolds can be used for biological and pharmaceutical studies of lineage-restricted stem cells, for maintenance of mature cells, and, in the future, for implantable, vascularized engineered tissues or organs. [Hepatology] Maturational Growth of Self-Assembled, Functional Menisci as a Result of TGF-Beta1 and Enzymatic Chondroitinase-ABC Stimulation In an effort to obtain the geometric properties and the maturational growth necessary for the recapitulation of biochemical and, thus, biomechanical properties, a scaffoldless cell-based system, the self-assembly process, was used in conjunction with the catabolic enzyme chondroitinase-ABC and TGF-beta1. [Biomaterials ] Bioactivation of Dermal Scaffolds with a Non-Viral Copolymer-Protected Gene Vector Researchers activated an FDA-approved collagen scaffold for dermal regeneration by incorporation of copolymer-protected gene vectors to induce a temporary release of VEGF. [Biomaterials] Distinct Roles for Paxillin and Hic-5 in Regulating Breast Cancer Cell Morphology, Invasion and Metastasis Researchers show that the focal adhesion adaptor protein, Paxillin and the closely related Hic-5, have distinct and unique roles in the regulation of breast cancer cell lung metastasis by modulating cell morphology and cell invasion through three dimensional extracellular matrices. [Mol Biol Cell] Integrin-Linked Kinase Is Required for TGF-Beta1 Induction of Dermal Myofibroblast Differentiation Researchers conclude that integrin-linked kinase is necessary to transduce signals implicated in the transition of dermal fibroblasts to myofibroblasts originating from matrix substrates and TGF-Beta1. [J Invest Dermatol] Promoting External Inosculation of Prevascularized Tissue Constructs by Pre-Cultivation in an Angiogenic Extracellular Matrix The engineering of preformed microvessels offers the promising opportunity to rapidly vascularize implanted tissue constructs by the process of inosculation. Herein, researchers analyzed whether this process may further be accelerated by cultivation of prevascularized tissue constructs in Matrigel before implantation. [Eur Cell Mater] Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1 Is Necessary for Normal Endochondral Ossification and Aggrecan Metabolism Observations suggest that chondroitin sulfate N-acetylgalactosaminyltransfease 1 is necessary for normal levels of endochondral ossification and the decrease in chondroitin sulfate amount in the growth plate by its absence causes a rapid catabolism of aggrecan. [J Biol Chem] Role of Integrins in Angiotensin II-Induced Proliferation of Vascular Smooth Muscle Cells To study crosstalk between GPCR- and integrin-induced signaling, researchers hypothesized that integrins are involved in AII-induced proliferation of vascular smooth muscle cells. [Am J Physiol Cell Physiol] Labeling of Fibronectin by Fluorescent and Paramagnetic Nanoprobes for Exploring the Extracellular Matrix: Bioconjugate Synthesis Optimization and Biochemical Characterization The local structure and global conformation of fibronectin-nanoparticle bioconjugates were studied by fluorescence spectroscopy and enzymatic sites accessibility. [Anal Bioanal Chem] Influence of Glial-Derived Matrix Molecules, Especially Chondroitin Sulfates, on Neurite Growth and Survival of Cultured Mouse Embryonic Motoneurons Results indicate that molecules of the extracellular matrix, especially chondroitin sulfates, play an important role as axon growth-promoting cues. [J Neurosci Res] Novel Tissue-Derived Biomimetic Scaffold for Regenerating the Human Nucleus Pulposus In the present study, researchers describe a novel approach to develop a tissue engineering scaffold comprised acellular porcine nucleus pulposus extracellular matrix. [J Biomed Mater Res A]
|
|
INDUSTRY NEWS Establishment of Olympus Biotech, and Its Acquisition of Osteogenic Protein-1 (OP-1) Assets from U.S.-Based Stryker Biotech Olympus Corporation announced the establishment of a new company, Olympus Biotech Corporation in the United States. Agreement has been reached with Stryker Corporation concerning Olympus Biotech’s acquisition from Stryker Biotech of a majority of assets in the bone field pertaining to the development, manufacture and sale of Osteogenic Protein-1. [Olympus Corporation Press Release] Harvard Bioscience Files Two Major Patents in Field of Regenerative Medicine Harvard Bioscience, Inc. has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth. [Harvard Bioscience, Inc. Press Release] First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation CorMatrix Cardiovascular, Inc. announced that Franciscan Alliance/St. Francis Heart Center in Indianapolis, Indiana is the first site to enroll a patient in the multi-center clinical trial of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation. [PR Newswire] New Dermagraft Coding to Streamline Reimbursement Process for Medicare Providers Advanced BioHealing, Inc. announced the Centers for Medicare and Medicaid Services has assigned two new procedure codes for the application of Dermagraft®, effective January 1, 2011. [Advanced BioHealing, Inc. Press Release] Halozyme Announces Roche Completes Patient Enrollment in Phase III Clinical Trial with Subcutaneous Herceptin® Halozyme Therapeutics, Inc. announced that Roche has completed patient enrollment for the pivotal Phase III study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme’s Enhanze™ technology (rHuPH20, recombinant human hyaluronidase). [Halozyme Therapeutics, Inc. Press Release]
|
|
EVENTS (Listed by Date) Pharmacology in Stem Cells Research and Regenerative Medicine December 17, 2010 London, United Kingdom The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine December 17-19, 2010 Guangzhou, China Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition January 21-26, 2011 Vancouver, Canada Extracellular Matrix and Cardiovascular Remodeling January 23-28, 2011 Tahoe City, United States 5th Annual Stem Cells and Regenerative Medicine World Congress January 24-25, 2011 San Diego, United States BIO Asia International Partnering Conference January 24-25, 2011 Tokyo, Japan Phacilitate 7th Annual Cell & Gene Therapy Forum 2011 January 24-26, 2011 Washington, D.C., United States IQPC’s 4th Biobanking Conference January 24-26, 2011 Philadelphia, United States AACR-ACS Joint Meeting on Chemistry in Cancer Research: The Biological Chemistry of Inflammation as a Cause of Cancer January 30-February 2, 2011 San Diego, United States Molecular Medicine Tri-Conference: Stem Cells – Revolutionizing Regenerative Medicine and Personalized Therapy 2011 February 23-25, 2011 San Francisco, United States Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture February 28-March 2, 2011 Munich, Germany PITTCON Conference & Expo 2011 March 13-18, 2011 Atlanta, United States 15th Annual Hilton Head Workshop – Regenerative Medicine, Innovations for Clinical Applications March 16-19, 2011 Hilton Head Island, United States United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom World Stem Cells & Regenerative Medicine Congress 2011 May 9-11, 2011 London, United Kingdom 13th Annual C21 BioVentures May 24-26, 2011 Napa, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Lab Technologist – Cell Separation (STEMCELL Technologies) Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Extracellular Matrix News? Click here to submit! |
|
|
|